Show simple item record

Phase I study of recombinant DNA granulocyte macrophage colony stimulating factor.

dc.contributor.authorSteward, William P
dc.contributor.authorScarffe, J Howard
dc.contributor.authorAustin, R
dc.contributor.authorCrowther, Derek
dc.date.accessioned2010-11-22T15:38:40Z
dc.date.available2010-11-22T15:38:40Z
dc.date.issued1988-08
dc.identifier.citationPhase I study of recombinant DNA granulocyte macrophage colony stimulating factor. 1988 (83):324-6 Behring Inst Mitten
dc.identifier.issn0301-0457
dc.identifier.pmid3071348
dc.identifier.urihttp://hdl.handle.net/10541/115979
dc.description.abstractIn this Phase I study of rh GM-CSF three patients have been entered at each of the following dose levels--0.3, 1, 3, 10 and 30 micrograms/kg/day. The mean total white cell count (x 10(9)/l) over the first ten days of rh GM-CSF rose from 11 to 14 at 3 micrograms/kg, 8 to 23 at 10 micrograms/kg and 7 to 27 at 30 micrograms/kg. Side effects included transient pyrexias after the first two infusions of rh GM-CSF and bone pains which were severe and required analgesia in two patients receiving 30 micrograms/kg and one receiving 10 micrograms/kg. No neutralizing antibodies to rh GM-CSF have been detected in the six patients tested to date. Patients are now being studied at 60 micrograms/kg/day.
dc.language.isoenen
dc.subjectCanceren
dc.subjectColorectal Canceren
dc.subject.meshColony-Stimulating Factors
dc.subject.meshColorectal Neoplasms
dc.subject.meshDrug Evaluation
dc.subject.meshGranulocyte-Macrophage Colony-Stimulating Factor
dc.subject.meshGrowth Substances
dc.subject.meshHumans
dc.subject.meshLeukocyte Count
dc.subject.meshNeoplasms
dc.subject.meshNeutrophils
dc.subject.meshRecombinant Proteins
dc.titlePhase I study of recombinant DNA granulocyte macrophage colony stimulating factor.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital, Manchester, U.K.en
dc.identifier.journalBehring Institute Mitteilungenen
html.description.abstractIn this Phase I study of rh GM-CSF three patients have been entered at each of the following dose levels--0.3, 1, 3, 10 and 30 micrograms/kg/day. The mean total white cell count (x 10(9)/l) over the first ten days of rh GM-CSF rose from 11 to 14 at 3 micrograms/kg, 8 to 23 at 10 micrograms/kg and 7 to 27 at 30 micrograms/kg. Side effects included transient pyrexias after the first two infusions of rh GM-CSF and bone pains which were severe and required analgesia in two patients receiving 30 micrograms/kg and one receiving 10 micrograms/kg. No neutralizing antibodies to rh GM-CSF have been detected in the six patients tested to date. Patients are now being studied at 60 micrograms/kg/day.


This item appears in the following Collection(s)

Show simple item record